Has John Pandolfino, MD received payments from drug or device companies?

Yes. Drug and device makers reported $328,125 in general payments to John Pandolfino, MD across 192 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Pandolfino, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Pandolfino, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Pandolfino, MD

Gastroenterology · Chicago, ILNPI 1396770277

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (36.4%), consulting fees and other — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Medtronic at 39.1% of the total. Reporting peaked in 2019 at $101,092 and has fallen 57.7% since, to $42,757 in 2025. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$328,125in general payments, 2019–2025

Across 192 payments — averaging $1708.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$128K
Covidien LP$110K
Johnson & Johnson$34K
Phathom Pharmaceuticals, Inc.$31K
Medical Device Business Services, Inc.$12K
Takeda Pharmaceuticals U.S.A., Inc.$6K
plus $6K from 6 others

$33,575in research payments, 2019–2025

Across 15 payments — averaging $2238.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$31K
Covidien LP$3K

What the payments were for

Royalty or licence$60,38618%
Consulting fees$71,77722%
Speaking & faculty fees$119,49036%
Travel & lodging$11,3133%
Food & beverage$4,6771%
Other$60,48318%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	74	$128,189
Covidien LP	39	$110,463
Johnson & Johnson(2 entities)	17	$34,490
Phathom Pharmaceuticals, Inc.	24	$30,590
Medical Device Business Services, Inc.	13	$12,196
Takeda Pharmaceuticals U.S.A., Inc.	7	$5,895
Endogastric Solutions, Inc	6	$3,731
Redhill Biopharma Inc.	1	$1,665
Boston Scientific	7	$579
AbbVie	1	$165
Sanofi	2	$148
BD	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$328,125 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois →

Medicare billing

Part B allowed, 2024

$17,707

Medicare patients

152

Services billed

243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate	11	$11,719
Omeprazole	46	$646
Ondansetron OdtOndansetron	11	$457
Pantoprazole Sodium	32	$424
Famotidine	12	$136

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Chicago

David RubinChicago$1.5M
Stephen HanauerChicago$1.4M
Steven FlammChicago$1.3M
Darren BrennerChicago$1.1M
Russell CohenChicago$690K
Parambir DulaiChicago$668K
Christopher ChapmanChicago$645K
Saurabh KapurChicago$532K
Ikuo HiranoChicago$457K
Adam SteinChicago$438K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →